APhA names candidates for several roles
WASHINGTON, D.C. — The American Pharmacists Association announced candidates for its board of trustees, president-elect and honorary president roles. Elections for these positions will take place March 24-May 22, and APha members will have the opportunity to meet the candidates during its Annual Meeting and Exposition in San Francisco from March 24-27.
The candidates for president-elect 2018-2019 are Brad Tice and Rebecca W. Chater. The two pairs nominated for election to serve 2018-2021 terms on the APhA Board of Trustees are: Gregory A. Fox vs. Magaly Rodriguez de Bittner; and Sean Jeffery of Branford vs. Theresa Tolle. Stanley Shaw is unopposed as the candidate for honorary president.
Tice, PharmD, MBA, FAPhA, is the director/product leader of Medication Therapy Management for Cardinal Health. He received his bachelor of science from the University of Kansas in 1994 and PharmD in 1996. He also received an MBA from Vanderbilt University Owen School of Management in 2012. His career has spanned pharmacy wholesaler, entrepreneurial start-up, independent and chain community pharmacy, academia, and managed care.
Chater, RPh, MPH, FAPhA has been a career-long pioneer in innovative community-based clinical pharmacy practice. She earned both her B.S. in Pharmacy and Masters in Public Health from UNC-Chapel Hill. Chater is Executive Healthcare Strategist for Ateb, a healthcare technology company specializing in integration of community pharmacy into the broader healthcare system.
Fox, RPh, is a current APhA Trustee and Pharmacy Merchandiser for The Kroger Co.’s Central Marketing Area, encompassing Indiana, Illinois, and parts of Missouri, Michigan, and Ohio. His experience includes community, managed care, long term care, and consultant pharmacy. He served on numerous health insurance plan boards as a board member or P&T committee member. He received his pharmacy degree from the University of Cincinnati and is a graduate of the University of Mississippi APhA Community Pharmacy Business Management Program.
Magaly Rodriguez de Bittner, PharmD, BCPS, CDE, FAPhA, is a professor and associate dean for Clinical Services and Practice Transformation and executive director of the Center for Innovative Pharmacy Solutions at the University of Maryland School of Pharmacy. Currently, she is a fellow in Population Health at the University of Maryland Health System. Her role as a pharmacy faculty has led to the development of many nationally recognized innovative programs, including the Giant Diabetes Education Program and the Maryland P3 Program.
Jeffery, Pharm.D., CGP, FASCP, FNAP, AGSF, is director of Clinical Pharmacy Services at Integrated Care Partners, an accountable care organization responsible for Hartford Healthcare Group’s value-based practice transformation. His career has focused on implementing innovative patient care services for seniors that promote the value of pharmacists in care coordination. Currently, he is responsible for pharmacy network development and strategy, population health management, and support of an integrated care-management team.
Tolle, BPharm, FAPhA, has been owner of Bay Street Pharmacy in Sebastian, Fla., for the past 17 years. Prior to owning an independent pharmacy, she had practice experience in chain, long term care (consultant) pharmacy and hospital.
Shaw, Ph.D., FAPhA, FASHP, FFIP is a professor emeritus, Nuclear Pharmacy at Purdue University College of Pharmacy. He received a B.S. in Pharmacy and M.S. in Pharmaceutical Science from South Dakota State University and a Ph.D. in Bionucleonics from Purdue.
The American Pharmacists Association, founded in 1852 as the American Pharmaceutical Association, represents more than 63,000 practicing pharmacists, pharmaceutical scientists, student pharmacists, pharmacy technicians and others interested in advancing the profession.
Walgreens opens first Community specialty banner in Iowa
DEERFIELD, Ill. — Walgreens will be opening its first specialty pharmacy in Iowa next month, according to a report in The Des Moines Register.
The 2,000 square foot pharmacy will open under the Community, A Walgreens Pharmacy banner and will cater to patients with complex medical conditions such as cancer, HIV/AIDS and transplants.
Walgreens operates about 75 community specialty pharmacies and about 175 specialty pharmacies in hospitals and clinics, according to the company. Walgreens celebrated another Community, A Walgreens Pharmacy opening last week in Baton Rouge, La.
The Community, A Walgreens Pharmacy banner is part of Walgreens’s multi-channel approach to specialty pharmacy, which Walgreens Specialty Pharmacy Group VP Gerry Gleeson outlined to Drug Store News in a recent interview.
“These locations have access to not just the broad-based specialty products that are out there in some of the large categories, but also to controlled or limited distribution products from manufacturers,” Gleeson told Drug Store News. “It’s very rare that manufacturers let some of these products out into community pharmacies, and we see now that our model is very attractive to the biopharma community to be able to again deliver complex therapies to patients in the local communities.”
Bristol-Myers Squibb remains committed to Opdivo-Yervoy combo lung cancer treatment
PRINCETON, N.J. — Despite word a week ago that Bristol-Myers Squibb will not seek accelerated regulatory approval for a combination of its Opdivo (nivolumab) and Yervoy (ipilimumab) as a first-line treatment for lung cancer, the company asserted it is committed to the development of the drug combination.
“We have a broad front-line lung cancer program, which we expanded and strengthened over the last several months. We have four combination front-line lung studies that are ongoing. These studies are designed with the optionality we build into all of our studies,” Bristol-Myers CEO Giovanni Caforio said Thursday during the company’s 2016 fourth-quarter earnings conference call. “We are committed to the development of the combination of Yervoy plus Opdivo. As you know, the competitive landscape in this space has changed over the last nine to 12 months, and it could very well change again based on future data readouts. We believe through our broad development program we have an opportunity to play a meaningful role in the treatment of patients in the first-line lung cancer setting. And with this in mind, our [research and development] team is focused and well-resourced in front-line lung, and is constantly looking for ways to strengthen our program and bring forward new treatments.”
Caforio added lung cancer treatment is very important to the company, but it will also focus on a broad set of priorities beyond lung cancer in 2017.
Outside of oncology, said Caforio: “We will build on the strength of the brands we've established, with Eliquis and Orencia in the near term. Longer term, we are advancing our efforts to diversify our portfolio with new pipeline agents in heart failure, immunoscience and fibrosis.”
The U.S. Food and Drug Administration approved the regimen of Opdivo and Yervoy as a treatment for metastatic melanoma in October 2015.